Taking A Biopharma Public Via M&A During The Pandemic
Source: Life Science Leader
In this executive virtual roundtable (EVR) segment, Tom Frohlich, CBO of Chinook Therapeutics, discusses what led to the company opting to go public via a merger with Aduro Biotech in June 2020, along with the pros and cons of such an approach. Joining the conversation are David Perry, cofounder and chairman of Better Therapeutics, and Macrio Souza, CEO, Praxis Precision Medicines.
This website uses cookies to ensure you get the best experience on our website. Learn more